Post hoc analysis of initial treatments and control status in the INITIAL study: an observational study of newly diagnosed patients with asthma.
Administration, Inhalation
Adrenal Cortex Hormones
/ administration & dosage
Adult
Anti-Asthmatic Agents
/ administration & dosage
Asthma
/ drug therapy
China
Delayed-Action Preparations
Drug Combinations
Female
Humans
Leukotriene Antagonists
/ administration & dosage
Male
Middle Aged
Prospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome
Global initiative for asthma
Inhaled corticosteroid
Leukotriene receptor antagonist
Long-acting β2 agonist
Symptom control
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
09 Apr 2020
09 Apr 2020
Historique:
received:
22
02
2019
accepted:
30
01
2020
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
26
1
2021
Statut:
epublish
Résumé
The 12-week, multicentre, observational INITIAL study (NCT02143739) assessed asthma severity in newly diagnosed Chinese patients. Post hoc analysis of medication combinations prescribed per routine clinical practice at baseline, and the impact on control levels evaluated using 2012 vs 2018 Global Initiative for Asthma (GINA) criteria. In total, 4491 patients were included in the analysis. At baseline, intermittent, mild, moderate and severe asthma was reported in 3.9, 12.0, 22.6 and 61.6% of patients, respectively. Most patients (90.2%) were prescribed inhaled corticosteroid/long-acting β Asthma control was not improved by adding LTRA to ICS/LABA and may have been unnecessary for some newly diagnosed patients. These findings were irrespective of the GINA criteria (2012 vs 2018) used and baseline severity.
Sections du résumé
BACKGROUND
BACKGROUND
The 12-week, multicentre, observational INITIAL study (NCT02143739) assessed asthma severity in newly diagnosed Chinese patients.
METHODS
METHODS
Post hoc analysis of medication combinations prescribed per routine clinical practice at baseline, and the impact on control levels evaluated using 2012 vs 2018 Global Initiative for Asthma (GINA) criteria.
RESULTS
RESULTS
In total, 4491 patients were included in the analysis. At baseline, intermittent, mild, moderate and severe asthma was reported in 3.9, 12.0, 22.6 and 61.6% of patients, respectively. Most patients (90.2%) were prescribed inhaled corticosteroid/long-acting β
CONCLUSIONS
CONCLUSIONS
Asthma control was not improved by adding LTRA to ICS/LABA and may have been unnecessary for some newly diagnosed patients. These findings were irrespective of the GINA criteria (2012 vs 2018) used and baseline severity.
Identifiants
pubmed: 32272921
doi: 10.1186/s12890-020-1069-2
pii: 10.1186/s12890-020-1069-2
pmc: PMC7147012
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Asthmatic Agents
0
Delayed-Action Preparations
0
Drug Combinations
0
Leukotriene Antagonists
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Subventions
Organisme : Study design; collection, analysis, and interpretation of data; and medical writing support were funded by AstraZeneca, China.
ID : -
Références
Clin Chest Med. 2012 Sep;33(3):405-17
pubmed: 22929091
Prim Care Respir J. 2012 Sep;21(3):288-94
pubmed: 22751737
Respir Res. 2012 Jun 22;13:50
pubmed: 22726416
Eur Respir J. 2005 Jul;26(1):36-44
pubmed: 15994387
Rhinology. 1998 Jun;36(2):62-5
pubmed: 9695159
Chest. 2007 Oct;132(4):1151-61
pubmed: 17573515
Sci Rep. 2019 Feb 4;9(1):1254
pubmed: 30718519
NPJ Prim Care Respir Med. 2017 Dec 8;27(1):64
pubmed: 29222436
Cochrane Database Syst Rev. 2012 May 16;(5):CD002314
pubmed: 22592685
Br J Pharmacol. 1998 Jun;124(3):563-71
pubmed: 9647482
J Thorac Dis. 2017 May;9(5):1333-1344
pubmed: 28616286
J Allergy Clin Immunol. 2001 Jan;107(1):61-7
pubmed: 11149992
Respir Med. 2006 Apr;100(4):616-21
pubmed: 16226443
Eur Respir J. 2010 Aug;36(2):269-76
pubmed: 20110397
Respir Med. 2001 May;95(5):319-23
pubmed: 11392570
BMC Pulm Med. 2009 May 19;9:24
pubmed: 19454036
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Eur Respir J. 1999 Oct;14(4):902-7
pubmed: 10573240
J Asthma. 2014 May;51(4):429-34
pubmed: 24304046
Thorax. 1994 Nov;49(11):1109-15
pubmed: 7831626
J Asthma. 2010 Oct;47(8):865-70
pubmed: 20846084
Curr Med Res Opin. 2004 Oct;20(10):1549-58
pubmed: 15462688
Am J Med. 2004 Mar 1;116(5):338-44
pubmed: 14984820